Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUBP 310 is a GluK1 (formerly GLUK5) kainate receptor antagonist (IC50 = 130 nM); also blocks recombinant homomeric GluK3 (forrmerly GLUK7) receptors. Displays 12,700-fold selectivity for GluK1 (formerly GLUK5) over GluK2 (formerly GLUK6). Exhibits no activity at mGlu group I or NMDA receptors at concentrations of up to 10 μM. Apparent KD value is 18 ± 4 nM for depression of kainate responses on the dorsal root.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
UBP 310 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 353.35 |
公式 | C14H15N3O6S |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 902464-46-4 |
PubChem ID | 6420160 |
InChI Key | ZTAZUCRXCRXNSU-VIFPVBQESA-N |
Smiles | CC1=CN(C[C@@H](C(O)=O)N)C(N(CC2=C(C(O)=O)SC=C2)C1=O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 7.07 | 20 |
以下数据基于产品分子量 353.35。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 14.15 mL | 70.75 mL | 141.5 mL |
1 mM | 2.83 mL | 14.15 mL | 28.3 mL |
2 mM | 1.42 mL | 7.08 mL | 14.15 mL |
10 mM | 0.28 mL | 1.42 mL | 2.83 mL |
参考文献是支持产品生物活性的出版物。
Mayer et al (2006) Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J.Neurosci. 26 2852 PMID: 16540562
Dolman et al (2007) Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: Role of the substituent at the 5-position of the uracil ring in development of highly potent and selective GLUK5 kainate receptor antagonists. J.Med.Chem. 50 1558 PMID: 17348638
Perrais et al (2009) Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology 56 131 PMID: 18761361
If you know of a relevant reference for UBP 310, please let us know.
关键词: UBP 310, UBP 310 supplier, UBP310, kainate, receptors, antagonists, GLUK5, iGlu, ionotropic, glutamate, GluK1, Kainate, Receptors, 3621, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 UBP 310 的部分引用包括:
Anna L et al (2021) Slow AMPA receptors in hippocampal principal cells. Cell Rep 36 109496 PMID: 34348150
Buldyrev et al (2012) Synaptic pathways that shape the excitatory drive in an OFF retinal ganglion cell. J Neurophysiol 107 1795 PMID: 22205648
Crook et al (2014) A synaptic signature for ON- and OFF-center parasol ganglion cells of the primate retina. Vis Neurosci 31 57 PMID: 24801624
Pollok and Reiner (2020) Subunit-selective iGluR antagonists can potentiate heteromeric receptor responses by blocking desensitization Proc Natl Acad Sci USA 117 25851 PMID: 32999066
Takeshi et al (2017) Kinetics of Releasable Synaptic Vesicles and Their Plastic Changes at Hippocampal Mossy Fiber Synapses. Neuron 96 1033-1040.e3 PMID: 29103807
您是否知道使用了 Tocris UBP 310 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review UBP 310 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.